Motor neuron disease: A chemical perspective

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6316-6331

  Wood, Laura K ^a   Langford, Steven J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; COPPER; GLUTAMATE TRANSPORTER; GROWTH FACTOR; MINOCYCLINE; NEUROPROTECTIVE AGENT; NIMODIPINE; REACTIVE OXYGEN METABOLITE; RILUZOLE; SUPEROXIDE DISMUTASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL MEMBRANE; CLINICAL TRIAL (TOPIC); DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; FENTON REACTION; GAIN OF FUNCTION MUTATION; HUMAN; LIPID PEROXIDATION; MOTOR NEURON DISEASE; MOUSE MODEL; MUTATION; NERVE CELL GROWTH; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RNA TRANSLATION; VITAMIN SUPPLEMENTATION; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; METABOLISM; MITOCHONDRION; TRANSGENIC MOUSE;

AMINO ACID TRANSPORT SYSTEM X-AG; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GLUTAMIC ACID; HUMANS; MICE, TRANSGENIC; MITOCHONDRIA; MUTATION; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUTAMATE; SUPEROXIDE DISMUTASE;

EID: 84906080179     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5001584     Document Type: Review

References (196)

1. Shukla, V.; Mishra, S. K.; Pant, H. C. Oxidative Stress in Neurodegeneration Adv. Pharmacol. Sci. 2011, 572634
2. Cui, H.; Kong, Y.; Zhang, H. Oxidative Stress, Mitochondrial Dysfunction, and Aging J. Signal Transduction 2012, 646354
3. Ferraiuolo, L.; Kirby, J.; Grierson, A. J.; Sendtner, M.; Shaw, P. J. Molecular Pathways of Motor Neuron Injury in Amyotrophic Lateral Sclerosis Nat. Rev. Neurol. 2011, 7, 616-630
4. Contestabile, A. Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives Curr. Med. Chem. 2011, 18, 5655-5665
5. Kiernan, M. C.; Vucic, S.; Cheah, B. C.; Turner, M. R.; Eisen, A.; Hardiman, O.; Burrell, J. R.; Zoing, M. C. Amyotrophic Lateral Sclerosis Lancet 2011, 377, 942-955
6. Joyce, P.; Fratta, P.; Fisher, E.; Acevedo-Arozena, A. SODI and TDP-43 Animal Models of Amyotrophic Lateral Sclerosis: Recent Advances in Understanding Disease Toward the Development of Clinical Treatments Mamm. Genome 2011, 22, 420-448
7. Roelofs-Iverson, R. A.; Mulder, D. W.; Elveback, L. R.; Kurland, L. T.; Molgaard, C. A. Neurology 1984, 34, 393-395
8. Pablo, J.; Banack, S. A.; Cox, P. A.; Johnson, T. E.; Papapetropoulos, S.; Bradley, W. G.; Buck, A.; Mash, D. C. Acta Neurol. Scand. 2009, 120, 216-225
9. Swarup, V.; Julien, J.-P. ALS Pathogenesis: Recent Insights from Genetics and Mouse Models Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 363-369
10. Tucker, T.; Layzer, R. B.; Miller, R. G.; Chad, D. Subacute, Reversible Motor Neuron Disease Neurology 1991, 41, 1541-1544
11. Tsai, C. P.; Ho, H. H.; Yen, D. J.; Wang, V.; Lin, K. P.; Liao, K. K.; Wu, Z. A. Reversible Motor Neuron Disease Eur. Neurol. 1993, 33, 387-389
12. Bensimon, G.; Lacomblez, L.; Meininger, V.; ALS/Riluzole Study Group. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis N. Engl. J. Med. 1994, 330, 585-591
13. Lacomblez, L.; Bensimon, G.; Meininger, V.; Leigh, P. N.; Guillet, P. Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis Lancet 1996, 347, 1425-1431
14. Miller, R. G.; Mitchell, J. D.; Lyon, M.; Moore, D. H. Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Amyotrophic Lateral Scler. 2003, 4, 191-206
15. Kiernan, M. C. Riluzole: A Glimmer of Hope in the Treatment of Motor Neurone Disease Med. J. Aust. 2005, 182, 319-320
16. Bensimon, G.; Doble, A. The Tolerability of Riluzole in the Treatment of Patients with Amyotrophic Lateral Sclerosis Expert Opin. Drug Saf. 2004, 3, 525-534
17. Bensimon, G.; Lacomblez, L.; Delumeau, J. C.; Bejuit, R.; Truffinet, P.; Meininger, V.; ALS Study Group II. A Study of Riluzole in the Treatment of Advanced Stage or Elderly Patients with Amyotrophic Lateral Sclerosis J. Neurol. 2002, 249, 609-615
18. Strong, M. J.; Hudson, A. J.; Alvord, W. G. Familial Amyotrophic Lateral Sclerosis; 1850-1989 Can. J. Neurol. Sci. 1991, 18, 45-58
19. Rosen, D. R.; Siddique, T.; D, P.; Figlewicz, D. A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J. P.; Deng, H. X. Mutations in Cu/Zn Superoxide Dismutase Gene are Associated with Familial Amyotrophic Lateral Sclerosis Nature 1993, 362, 59-62
20. Cudkowicz, M. E.; McKenna-Yasek, D.; Sapp, P. E.; Chin, W.; Geller, B.; Hayden, D. L.; Schoenfeld, D. A.; Hosler, B. A.; Horvitz, H. R.; Brown, R. H. Epidemiology of Mutations in Superoxide Dismutase in Amyotrophic Lateral Sclerosis Ann. Neurol. 1997, 41, 210-221
21. Eisen, A.; Schulzer, M.; MacNeil, M.; Pant, B.; Mak, E. Duration of Amyotrophic Lateral Sclerosis is Age Dependent Muscle Nerve 1993, 16, 27-32
22. Haverkamp, L. J.; Appel, V.; Appel, S. H. Natural History of Amyotrophic Lateral Sclerosis in a Database Population: Validation of a Scoring System and a Model for Survival Prediction Brain 1995, 118, 707-719
23. Grohme, K.; v. Maravic, M.; Gasser, T.; Borasio, G. D. A Case of Amyotrophic Lateral Sclerosis with a Very Slow Progression Over 44 years Neuromuscular Disord. 2001, 11, 414-416
24. Andersen, P. M.; Forsgren, L.; Binzer, M.; Nilsson, P.; Ala-Hurula, V.; Keranen, M.-L.; Bergmark, L.; Saarinen, A.; Haltia, T.; Tarvainen, I.; Kinnunen, E.; Udd, B.; Marklund, S. L. Autosomal Recessive Adult-Onset Amyotrophic Lateral Sclerosis Associated with Homozygosity for Asp90Ala CuZn-superoxide Dismutase Mutation: A Clinical and Genealogical Study of 36 Patients Brain 1996, 119, 1153-1172
25. Rosen, D. R.; Bowling, A. C.; Patterson, D.; Usdin, T. B.; Sapp, P.; Mezey, E.; McKenna-Yasek, D.; O'Regan, J.; Rahmani, Z.; Ferrante, R. J.; Brownstein, M. J.; Kowall, N. W.; Beal, M. F.; Horvitz, H. R.; Brown, R. H. A Frequent Ala 4 to Val Superoxide Dismutase-1 Mutation Is Associated with a Rapidly Progressive Familial Amyotrophic Lateral Sclerosis Hum. Mol. Genet. 1994, 3, 981-987
26. Andersen, P. M.; Borasio, G. D.; Dengler, R.; Hardiman, O.; Kollewe, K.; Leigh, P. N.; Pradat, P.-F.; Silani, V.; Tomik, B. EFNS Task Force on Management of Amyotrophic Lateral Sclerosis: Guidelines for Diagnosing and Clinical Care of Patients and Relatives Eur. J. Neurol. 2005, 12, 921-938
27. Deng, H.-X.; Hentati, A.; Tainer, J. A.; Iqbal, Z.; Cayabyab, A.; Hung, W.-Y.; Getzoff, E. D.; Hu, P.; Herzfeldt, B.; Roos, R. P.; Warner, C.; Deng, G.; Soriano, E.; Smyth, C.; Parge, H. E.; Ahmed, A.; Roses, A. D.; Hallewell, R. A.; Pericak-Vance, M. A.; Siddique, T. Amyotrophic Lateral Sclerosis and Structural Defects in Cu,Zn Superoxide Dismutase Science 1993, 261, 1047-1051
28. Milani, P.; Gagliardi, S.; Cova, E.; Cereda, C. SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS Neurol. Res. Int. 2011, 1-9
29. Duffy, L. M.; Chapman, A. L.; Shaw, P. J.; Grierson, A. J. The Role of Mitochondria in the Pathogenesis of Amyotrophic Lateral Sclerosis Neuropathol. Appl. Neurobiol. 2011, 37, 336-352
30. Faes, L.; Callewaert, G. Itochondrial Dysfunction in Familial Amyotrophic Lateral Sclerosis J. Bioenerg. Biomembr. 2011, 43, 587-592
31. Reddy, P. H.; Reddy, T. P. Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases Curr. Alzheimer Res. 2011, 8, 393-409
32. McCord, J. M.; Fridovich, I. Superoxide Dismutase: An Enzymic Function for Erythrocuprein (Hemocuprein) J. Biol. Chem. 1969, 244, 6049-6055
33. Cozzolino, M.; Ferri, A.; Carrì, M. T. Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications Antioxid. Redox Signaling 2008, 10, 405-444
34. Sreedharan, J. Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics? CNS Neurol. Disord.: Drug Targets 2010, 9, 259-267
35. Shibata, N. Transgenic Mouse Model for Familial Amyotrophic Lateral Lclerosis with Superoxide Dismutase-1 Mutation Neuropathology 2001, 21, 82-92
36. Gurney, M. E.; Pu, H.; Chiu, A. Y.; Canto, M. C. D.; Polchow, C. Y.; Alexander, D. D.; Caliendo, J.; Hentati, A.; Kwon, Y. W.; Deng, H.-X.; Chen, W.; Zhai, P.; Sufit, R. L.; Siddique, T. Motor Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide Dismutase Mutation Science 1994, 264, 1772-1775
37. Wong, P. C.; Pardo, C. A.; Borchelt, D. R.; Lee, M. K.; Copeland, N. G.; Jenkins, N. A.; Sisodia, S. S.; Cleveland, D. W.; Price, D. L. An Adverse Property of a Familial ALS-Linked SOD1 Mutation Causes Motor Neuron Disease Characterized by Vacuolar Degeneration of mitochondria Neuron 1995, 14, 1105-1116
38. Ripps, M. E.; Huntley, G. W.; Hof, P. R.; Morrison, J. H.; Gordon, J. W. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 689-693
39. Bruijn, L. I.; Becher, M. W.; Lee, M. K.; Anderson, K. L.; Jenkins, N. A.; Copeland, N. G.; Sisodia, S. S.; Rothstein, J. D.; Borchelt, D. R.; Price, D. L.; Cleveland, D. W. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions Neuron 1997, 18, 327-338
40. Benatar, M. Treatment Trials in the SOD1 Mouse and in Human ALS Neurobiol. Dis. 2007, 26, 1-13
41. Klivenyi, P.; Ferrante, R. J.; Matthews, R. T.; Bogdanov, M. B.; Klein, A. M.; Andreassen, O. A.; Mueller, G.; Wermer, M.; Kaddurah-Daouk, R.; Beal, M. F. Neuroprotective Effects of Creatine in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis Nat. Med. 1999, 5, 347-350
42. Beal, M. Neuroprotective Effects of Creatine Amino Acids 2011, 40, 1305-1313
43. Groeneveld, G. J.; Veldink, J. H.; Tweel, I. v. d.; Kalmijn, S.; Beijer, C.; Visser, M. d.; Wokke, J. H. J.; Franssen, H.; Berg, L. H. v. d. A Randomized Sequential Trial of Creatine in Amyotrophic Lateral Sclerosis Ann. Neurol. 2003, 53, 437-445
44. Carrì, M. T.; Grignaschi, G.; Bendotti, C. Targets in ALS: designing multidrug therapies Trends Pharmacol. Sci. 2006, 27, 267-273
45. Gurney, M. E.; Fleck, T. J.; Himes, C. S.; Hall, E. D. Riluzole Preserves Motor Function in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis Neurology 1998, 50, 62-66
46. Bruijn, L. I.; Houseweart, M. K.; Kato, S.; Anderson, K. L.; Anderson, S. D.; Ohama, E.; Reaume, A. G.; Scott, R. W.; Cleveland, D. W. Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1 Science 1998, 281, 1851-1854
47. Reaume, A. G.; Elliott, J. L.; Hoffman, E. K.; Kowall, N. W.; Ferrante, R. J.; Siwek, D. R.; Wilcox, H. M.; Flood, D. G.; Beal, M. F.; Brown, R. H.; Scott, R. W.; Snider, W. D. Motor Neurons in Cu/Zn Superoxide Dismutase-Deficient Mice Develop Normally but Exhibit Enhanced Cell Death after Axonal Injury Nat. Genet. 1996, 13, 43-47
48. Liu, R.; Althaus, J. S.; Ellerbrock, B. R.; Becker, D. A.; Gurney, M. E. Enhanced Oxygen Radical Production in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis Ann. Neurol. 1998, 44, 763-770
49. Kruman, I. I.; Pedersen, W. A.; Springer, J. E.; Mattson, M. P. ALS-Linked Cu/Zn-SOD Mutation Increases Vulnerability of Motor Neurons to Excitotoxicity by a Mechanism Involving Increased Oxidative Stress and Perturbed Calcium Homeostasis Exp. Neurol. 1999, 160, 28-39
50. Ghadge, G. D.; Lee, J. P.; Bindokas, V. P.; Jordan, J.; Ma, L.; Miller, R. J.; Roos, R. P. Mutant Superoxide Dismutase-1-Linked Familial Amyotrophic Lateral Sclerosis: Molecular Mechanisms of Neuronal Death and Protection J. Neurosci. 1997, 17, 8756-8766
51. Liu, D.; Wen, J.; Liu, J.; Li, L. The Roles of Free Radicals in Amyotrophic Lateral Sclerosis: Reactive Oxygen Species and Elevated Oxidation of Protein, DNA, and Membrane Phospholipids FASEB J. 1999, 13, 2318-2328
52. Liu, R.; Li, B.; Flanagan, S. W.; Oberley, L. W.; Gozal, D.; Qiu, M. Increased Mitochondrial Antioxidative Activity or Decreased Oxygen Free Radical Propagation Prevent Mutant SOD1-Mediated Motor Neuron Cell Death and Increase Amyotrophic Lateral Sclerosis-like Transgenic Mouse Survival J. Neurochem. 2002, 80, 488-500
53. Wiedau-Pazos, M.; Goto, J. J.; Rabizadeh, S.; Gralla, E. B.; Roe, J. A.; Lee, M. K.; Valentine, J. S.; Bredesen, D. E. Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis Science 1996, 271, 515-518
54. Yim, H.-S.; Kang, J.-H.; Chock, P. B.; Stadtman, E. R.; Yim, M. B. A Familial Amyotrophic Lateral Sclerosis-Associated A4V Cu,Zn-Superoxide Dismutase Mutant Has a Lower Km for Hydrogen Peroxide J. Biol. Chem. 1997, 272, 8861-8863
55. Yim, M. B.; Kang, J. H.; Yim, H. S.; Kwak, H. S.; Chock, P. B.; Stadtman, E. R. A Gain-of-Function of an Amyotrophic Lateral Sclerosis-Associated Cu,Zn-Superoxide Dismutase Mutant: An Enhancement of Free Radical Formation Due to a Decrease in Km for Hydrogen Peroxide Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5709-5714
56. Wang, J.; Slunt, H.; Gonzales, V.; Fromholt, D.; Coonfield, M.; Copeland, N. G.; Jenkins, N. A.; Borchelt, D. R. Copper-Binding-Site-Null SOD1 Causes ALS in Transgenic Mice: Aggregates of Non-Native SOD1 Delineate a Common Feature Hum. Mol. Genet. 2003, 12, 2753-2764
57. Subramaniam, J. R.; Lyons, W. E.; Liu, J.; Bartnikas, T. B.; Rothstein, J.; Price, D. L.; Cleveland, D. W.; Gitlin, J. D.; Wong, P. C. Mutant SOD1 Causes Motor Neuron Disease Independent of Copper Chaperone-Mediated Copper Loading Nat. Neurosci. 2002, 5, 301-307
58. Johnston, J. A.; Dalton, M. J.; Gurney, M. E.; Ron, R. K. Formation of High Molecular Weight Complexes of Mutant Cu,Zn-Superoxide Dismutase in a Mouse Model for Familial Amyotrophic Lateral Sclerosis Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12571-12576
59. Rakhit, R.; Cunningham, P.; Furtos-Matei, A.; Dahan, S.; Qi, X.-F.; Crow, J. P.; Cashman, N. R.; Kondejewski, L. H.; Chakrabartty, A. Oxidation-Induced Misfolding and Aggregation of Superoxide Dismutase and Its Implications for Amyotrophic Lateral Sclerosis J. Biol. Chem. 2002, 277, 47551-47556
60. Pasinelli, P.; Belford, M. E.; Lennon, N.; Bacskai, B. J.; Hyman, B. T.; Trotti, D.; Brown, R. H., Jr. Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria Neuron 2004, 43, 19-30
61. Carrì, M.; Cozzolino, M. SOD1 and Mitochondria in ALS: A Dangerous Liaison J. Bioenerg. Biomembr. 2011, 43, 593-599
62. Shi, P.; Gal, J.; Kwinter, D. M.; Liu, X.; Zhu, H. Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis Biochim. Biophys. Acta 2010, 1802, 45-51
63. Filosto, M.; Scarpelli, M.; Cotelli, M.; Vielmi, V.; Todeschini, A.; Gregorelli, V.; Tonin, P.; Tomelleri, G.; Padovani, A. The Role of Mitochondria in Neurodegenerative Diseases J. Neurol. 2011, 258, 1763-1774
64. Kirkinezos, I. G.; Bacman, S. R.; Hernandez, D.; Oca-Cossio, J.; Arias, L. J.; Perez-Pinzon, M. A.; Bradley, W. G.; Moraes, C. T. Cytochrome c Association with the Inner Mitochondrial Membrane Is Impaired in the CNS of G93A-SOD1 Mice J. Neurosci. 2005, 25, 164-172
65. Mattiazzi, M.; D'Aurelio, M.; Gajewski, C. D.; Martushova, K.; Kiaei, M.; Beal, M. F.; Manfredi, G. Mutated Human SOD1 Causes Dysfunction of Oxidative Phosphorylation in Mitochondria of Transgenic Mice J. Biol. Chem. 2002, 277, 29626-29633
66. Warita, H.; Hayashi, T.; Murakami, T.; Manabe, Y.; Abe, K. Oxidative Damage to Mitochondrial DNA in Spinal Motoneurons of Transgenic ALS Mice Mol. Brain Res. 2001, 89, 147-152
67. Wiedemann, F. R.; Manfredi, G.; Mawrin, C.; Beal, M. F.; Schon, E. A. Mitochondrial DNA and Respiratory Chain Function in Spinal Cords of ALS Patients J. Neurochem. 2002, 80, 616-625
68. Holcik, M.; LaCasse, E.; MacKenzie, A.; Korneluk, R., Eds. Apoptosis in Health and Disease: Clinical and Therapeutic Aspects, 1 st ed.; Cambridge University Press: Cambridge, U.K., 2005.
69. Caroppi, P.; Sinibaldi, F.; Fiorucci, L.; Santucci, R. Apoptosis and Human Diseases: Mitochondrion Damage and Lethal Role of Released Cytochrome c as Proapoptotic Protein Curr. Med. Chem. 2009, 16, 4058-4065
70. Guégan, C.; Vila, M.; Rosoklija, G.; Hays, A. P.; Przedborski, S. Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis J. Neurosci. 2001, 21, 6569-6576
71. Naoi, M.; Maruyama, W.; Yi, H.; Inaba, K.; Akao, Y.; Shamoto-Nagai, M. Mitochondria in Neurodegenerative Disorders: Regulation of the Redox State and Death Signaling Leading to Neuronal Death and Survival J. Neural Transm. 2009, 116, 1371-1381
72. Ribe, E. M.; Serrano-saiz, E.; Akpan, N.; Troy, C. M. Mechanisms of Neuronal Death in Disease: Defining the Models and the Players Biochem. J. 2008, 415, 165-182
73. Manfredi, G.; Xu, Z. Mitochondrial Dysfunction and Its Role in Motor Neuron Degeneration in ALS Mitochondrion 2005, 5, 77-87
74. Bossy-Wetzel, E.; Newmeyer, D. D.; Green, D. R. Mitochondrial Cytochrome c Release in Apoptosis Occurs Upstream of DEVD-Specific Caspase Activation and Independently of Mitochondrial Transmembrane Depolarization EMBO J. 1998, 17, 37-49
75. Pasinelli, P.; Houseweart, M. K.; Brown, R. H., Jr.; Don, W. C. Caspase-1 and-3 Are Sequentially Activated in Motor Neuron Death in Cu,Zn Superoxide Dismutase-Mediated Familial Amyotrophic Lateral Sclerosis Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13901-13906
76. Li, M.; Ona, V. O.; Guégan, C.; Chen, M.; Jackson-Lewis, V.; Andrews, L. J.; Olszewski, A. J.; Stieg, P. E.; Lee, J.-P.; Przedborski, S.; Friedlander, R. M. Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model Science 2000, 288, 335-339
77. Friedlander, R. M.; Brown, R. H.; Gagliardini, V.; Wang, J.; Yuan, J. Inhibition of ICE Slows ALS in Mice Nature 1997, 388, 31-32
78. Ferri, A.; Cozzolino, M.; Crosio, C.; Nencini, M.; Casciati, A.; Gralla, E. B.; Rotilio, G.; Valentine, J. S.; Carrì, M. T. Familial ALS-Superoxide Dismutases Associate with Mitochondria and Shift their Redox Potentials Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13860-13865
79. Takeuchi, H.; Kobayashi, Y.; Ishigaki, S.; Doyu, M.; Sobue, G. Mitochondrial Localization of Mutant Superoxide Dismutase 1 Triggers Caspase-Dependent Cell Death in a Cellular Model of Familial Amyotrophic Lateral Sclerosis J. Biol. Chem. 2002, 277, 50966-50972
80. Yang, Y.; Hentati, A.; Deng, H.-X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.-Y.; Ouahchi, K.; Yan, J.; Azim, A. C.; Cole, N.; Gascon, G.; Yagmour, A.; Ben-Hamida, M.; Pericak-Vance, M.; Hentati, F. The Gene Encoding Alsin, a Protein with Three Guanine-Nucleotide Exchange Factor Domains, Is Mutated in a Form of Recessive Amyotrophic Lateral Sclerosis Nat. Genet. 2001, 29, 160-165
81. Hadano, S.; Hand, C. K.; Osuga, H.; Yanagisawa, Y.; Otomo, A.; Devon, R. S.; Miyamoto, N.; Showguchi-Miyata, J.; Okada, Y.; Singaraja, R.; Figlewicz, D. A.; Kwiatkowski, T.; Hosler, B. A.; Sagie, T. A Gene Encoding a Putative GTPase Regulator Is Mutated in Familial Amyotrophic Lateral Sclerosis Nat. Genet. 2001, 29, 166-173
82. Chen, Y.-Z.; Bennett, C. L.; Huynh, H. M.; Blair, I. P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M. L.; Rabin, B. A.; Nicholson, G. A.; Auer-Grumbach, M.; Wagner, K.; De Jonghe, P.; Griffin, J. W.; Fischbeck, K. H.; Timmerman, V.; Cornblath, D. R.; Chance, P. F. DNA/RNA Helicase Gene Mutations in a Form of Juvenile Amyotrophic Lateral Sclerosis (ALS4) Am. J. Hum. Genet. 2004, 74, 1128-1135
83. Nishimura, A. L.; Mitne-Neto, M.; Silva, H. C. A.; Richieri-Costa, A.; Middleton, S.; Cascio, D.; Kok, F.; Oliveira, J. R. M.; Gillingwater, T.; Webb, J.; Skehel, P.; Zatz, M. A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis Am. J. Hum. Genet. 2004, 75, 822-831
84. Neumann, M.; Sampathu, D. M.; Kwong, L. K.; Truax, A. C.; Micsenyi, M. C.; Chou, T. T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C. M.; McCluskey, L. F.; Miller, B. L.; Masliah, E.; Mackenzie, I. R.; Feldman, H.; Feiden, W.; Kretzschmar, H. A.; Trojanowski, J. Q.; Lee, V. M.-Y. Ubiquitinated TDP-43 in Frontotemporal Lombar Degeneration and Amyotrophic Lateral Sclerosis Science 2006, 314, 130-133
85. Mackenzie, I. R. A.; Bigio, E. H.; Ince, P. G.; Geser, F.; Neumann, M.; Cairns, N. J.; Kwong, L. K.; Forman, M. S.; Ravits, J.; Stewart, H.; Eisen, A.; McClusky, L.; Kretzschmar, H. A.; Monoranu, C. M.; Highley, J. R.; Kirby, J.; Siddique, T.; Shaw, P. J.; Lee, V. M. Y.; Trojanowski, J. Q. Pathological TDP-43 Distinguishes Sporadic Amyotrophic Lateral Sclerosis from Amyotrophic Lateral Sclerosis with SOD1 Mutations Ann. Neurol. 2007, 61, 427-434
86. Sreedharan, J.; Blair, I. P.; Tripathi, V. B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J. C.; Williams, K. L.; Buratti, E.; Baralle, F.; de Belleroche, J.; Mitchell, J. D.; Leigh, P. N.; Al-Chalabi, A.; Miller, C. C.; Nicholson, G.; Shaw, C. E. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis Science 2008, 319, 1668-1672
87. Tan, C.-F.; Eguchi, H.; Tagawa, A.; Onodera, O.; Iwasaki, T.; Tsujino, A.; Nishizawa, M.; Kakita, A.; Takahashi, H. TDP-43 Immunoreactivity in Neuronal Inclusions in Familial Amyotrophic Lateral Sclerosis with or without SOD1 Gene Mutation Acta Neuropathol. 2007, 113, 535-542
88. Halliwell, B.; Gutteridge, J. M. C. Free Radicals in Biology and Medicine, 4 th ed.; Oxford University Press: Oxford, U.K., 2007.
89. Adibhatla, R. M.; Hatcher, J. F. Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities Antioxid. Redox Signaling 2010, 12, 125-169
90. Hall, E. D.; Andrus, P. K.; Oostveen, J. A.; Fleck, T. J.; Gurney, M. E. Relationship of Oxygen Radical-Induced Lipid Peroxidative Damage to Disease Onset and Progression in a Transgenic Model of Familial ALS J. Neurosci. Res. 1998, 53, 66-77
91. Ferrante, R. J.; Browne, S. E.; Shinobu, L. A.; Bowling, A. C.; Baik, M. J.; MacGarvey, U.; Kowall, N. W.; Brown, R. H., Jr.; Beal, M. F. Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis J. Neurochem. 1997, 69, 2064-2074
92. Beal, M. F.; Ferrante, R. J.; Browne, S. E.; Matthews, R. T.; Kowall, N. W.; Brown, R. H., Jr. Increased 3-Nitrotyrosine in Both Sporadic and Familial Amyotrophic Lateral Sclerosis Ann. Neurol. 1997, 42, 644-654
93. Ferrante, R. J.; Shinobu, L. A.; Schulz, J. B.; Matthews, R. T.; Thomas, C. E.; Kowall, N. W.; Gurney, M. E.; Beal, M. F. Increased 3-Nitrotyrosine and Oxidative Damage in Mice with a Human Copper/Zinc Superoxide Dismutase Mutation Ann. Neurol. 1997, 42, 326-334
94. Pedersen, W. A.; Fu, W.; Keller, J. N.; Markesbery, W. R.; Appel, S.; Smith, R. G.; Kasarskis, E.; Mattson, M. P. Protein Modification by the Lipid Peroxidation Product 4-Hydroxynonenal in the Spinal Cords of Amyotrophic Lateral Sclerosis Patients Ann. Neurol. 1998, 44, 819-824
95. Tohgi, H.; Abe, T.; Yamazaki, K.; Murata, T.; Ishizaki, E.; Isobe, C. Remarkable Increase in Cerebrospinal Fluid 3-Nitrotyrosine in Patients with Sporadic Amyotrophic Lateral Sclerosis Ann. Neurol. 1999, 46, 129-131
96. Markesbery, W. R.; Lovell, M. A. Four-hydroxynonenal, a Product of Lipid Peroxidation, Is Increased in the Brain in Alzheimer's Disease Neurobiol. Aging 1998, 19, 33-36
97. Fenton, H. J. H. Oxidation of Tartaric Acid in Presence of Iron J. Chem. Soc. 1894, 65, 899-903
98. Leveugle, B.; Spik, G.; Perl, D. P.; Bouras, C.; Fillit, H. M.; Hof, P. R. The Iron-Binding Protein Lactotransferrin Is Present in Pathologic Lesions in a Variety of Neurodegenerative Disorders: A Comparative Immunohistochemical Analysis Brain Res. 1994, 650, 20-31
99. Kasarskis, E. J.; Tandon, L.; Lovell, M. A.; Ehmann, W. D. Aluminum, Calcium, and Iron in the Spinal Cord of Patients with Sporadic Amyotrophic Lateral Sclerosis Using Laser Microprobe Mass Spectroscopy: A Preliminary Study J. Neurol. Sci. 1995, 130, 203-208
100. Wang, X.-S.; Lee, S.; Simmons, Z.; Boyer, P.; Scott, K.; Liu, W.; Connor, J. Increased Incidence of the Hfe Mutation in Amyotrophic Lateral Sclerosis and Related Cellular Consequences J. Neurol. Sci. 2004, 227, 27-33
101. Goodall, E. F.; Greenway, M. J.; van Marion, I.; Carroll, C. B.; Hardiman, O.; Morrison, K. E. Association of the H63D Polymorphism in the Hemochromatosis Gene with Sporadic ALS Neurology 2005, 65, 934-937
102. Olsen, M. K.; Roberds, S. L.; Ellerbrock, B. R.; Fleck, T. J.; McKinley, D. K.; Gurney, M. E. Disease Mechanisms Revealed by Transcription Profiling in SOD1-G93A Transgenic Mouse Spinal Cord Ann. Neurol. 2001, 50, 730-740
103. Hottinger, A. F.; Fine, E. G.; Gurney, M. E.; Zurn, A. D.; Aebischer, P. The Copper Chelator d-Penicillamine Delays Onset of Disease and Extends Survival in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis Eur. J. Neurosci. 1997, 9, 1548-1551
104. Azzouz, M.; Poindron, P.; Guettier, S.; Leclerc, N.; Andres, C.; Warter, J.-M.; Borg, J. Prevention of Mutant SOD1 Motor Neuron Degeneration by Copper Chelators in Vitro J. Neurobiol. 2000, 42, 49-55
105. Kiaei, M.; Bush, A. I.; Morrison, B. M.; Morrison, J. H.; Cherny, R. A.; Volitakis, I.; Beal, M. F.; Gordon, J. W. Genetically Decreased Spinal Cord Copper Concentration Prolongs Life in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis J. Neurosci. 2004, 24, 7945-7950
106. Hayward, L. J.; Rodriguez, J. A.; Kim, J. W.; Tiwari, A.; Goto, J. J.; Cabelli, D. E.; Valentine, J. S.; Brown, R. H. Decreased Metallation and Activity in Subsets of Mutant Superoxide Dismutases Associated with Familial Amyotrophic Lateral Sclerosis J. Biol. Chem. 2002, 277, 15923-15931
107. Gabbianelli, R.; Ferri, A.; Rotilio, G.; Carrì, M. T. Aberrant Copper Chemistry as a Major Mediator of Oxidative Stress in a Human Cellular Model of Amyotrophic Lateral Sclerosis J. Neurochem. 1999, 73, 1175-1180
108. Corson, L. B.; Strain, J. J.; Culotta, V. C.; Cleveland, D. W. Chaperone-Facilitated Copper Binding Is a Property Common to Several Classes of Familial Amyotrophic Lateral Sclerosis-Linked Superoxide Dismutase Mutants Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6361-6366
109. Lau, A.; Tymianski, M. Glutamate Receptors, Neurotoxicity and Neurodegeneration Pfluegers Arch. 2010, 460, 525-542
110. Le Verche, V.; Ikiz, B.; Jacquier, A. Glutamate Pathway Implication in Amyotrophic Lateral Sclerosis: What Is the Signal in the Noise? J. Recept., Ligand Channel Res. 2011, 4, 1-22
111. Grosskreutz, J.; Van Den Bosch, L.; Keller, B. U. Calcium Dysregulation in Amyotrophic Lateral Sclerosis Cell Calcium 2010, 47, 165-174
112. Rothstein, J. D.; Tsai, G.; Kuncl, R. W.; Clawson, L.; Cornblath, D. R.; Drachman, D. B.; Pestronk, A.; Stauch, B. L.; Coyle, J. T. Abnormal Excitatory Amino Acid Metabolism in Amyotrophic Lateral Sclerosis Ann. Neurol. 1990, 28, 18-25
113. Lafon-Cazal, M.; Pietri, S.; Culcasi, M.; Bockaert, J. NMDA-Dependent Superoxide Production and Neurotoxicity Nature 1993, 364, 535-537
114. Reynolds, I.; Hastings, T. Glutamate Induces the Production of Reactive Oxygen Species in Cultured Forebrain Neurons Following NMDA Receptor Activation J. Neurosci. 1995, 15, 3318-3327
115. Dugan, L.; Sensi, S.; Canzoniero, L.; Handran, S.; Rothman, S.; Lin, T.; Goldberg, M.; Choi, D. Mitochondrial Production of Reactive Oxygen Species in Cortical Neurons Following Exposure to N-Methyl-d-aspartate J. Neurosci. 1995, 15, 6377-6388
116. Stout, A. K.; Raphael, H. M.; Kanterewicz, B. I.; Klann, E.; Reynolds, I. J. Glutamate-Induced Neuron Death Requires Mitochondrial Calcium Uptake Nat. Neurosci. 1998, 1, 366-373
117. 2+ Homeostasis in the Regulation of Apoptotic and Necrotic Cell Deaths Cell Calcium 2000, 28, 107-117
118. +: Implications for Neurodegeneration J. Neurochem. 1994, 63, 584-591
119. Rattray, M.; Bendotti, C. Does Excitotoxic Cell Death of Motor Neurons in ALS Arise from Glutamate Transporter and Glutamate Receptor Abnormalities? Exp. Neurol. 2006, 201, 15-23
120. Bouvier, M.; Szatkowski, M.; Amato, A.; Attwell, D. The Glial Cell Glutamate Uptake Carrier Countertransports pH-Changing Anions Nature 1992, 360, 471-474
121. Kvamme, E.; Schousboe, A.; Hertz, L.; Torgner, I. A.; Svenneby, G. Developmental Change of Endogenous Glutamate and Gamma-Glutamyl Transferase in Cultured Cerebral Cortical Interneurons and Cerebellar Cranule Cells, and in Mouse Cerebral Cortex and Cerebellum in Vivo Neurochem. Res. 1985, 10, 993-1008
122. Shaw, P. J.; Forrest, V.; Ince, P. G.; Richardson, J. P.; Wastell, H. J. CSF and Plasma Amino Acid Levels in Motor Neuron Disease: Elevation of CSF Glutamate in a Subset of Patients Neurodegeneration 1995, 4, 209-216
123. Rothstein, J. D.; Martin, L.; Levey, A. I.; Dykes-Hoberg, M.; Jin, L.; Wu, D.; Nash, N.; Kuncl, R. W. Localization of Neuronal and Glial Glutamate Transporters Neuron 1994, 13, 713-725
124. Lehre, K.; Levy, L.; Ottersen, O.; Storm-Mathisen, J.; Danbolt, N. Differential Expression of Two Glial Glutamate Transporters in the Rat Brain: Quantitative and Immunocytochemical Observations J. Neurosci. 1995, 15, 1835-1853
125. Tanaka, K.; Watase, K.; Manabe, T.; Yamada, K.; Watanabe, M.; Takahashi, K.; Iwama, H.; Nishikawa, T.; Ichihara, N.; Kikuchi, T.; Okuyama, S.; Kawashima, N.; Hori, S.; Takimoto, M.; Wada, K. Epilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1 Science 1997, 276, 1699-1702
126. Howland, D. S.; Liu, J.; She, Y.; Goad, B.; Maragakis, N. J.; Kim, B.; Erickson, J.; Kulik, J.; DeVito, L.; Psaltis, G.; DeGennaro, L. J.; Cleveland, D. W.; Rothstein, J. D. Focal Loss of the Glutamate Transporter EAAT2 in a Transgenic Rat Model of SOD1 Mutant-Mediated Amyotrophic Lateral Sclerosis (ALS) Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1604-1609
127. Haugeto, Ø.; Ullensvang, K.; Levy, L. M.; Chaudhry, F. A.; Honoré, T.; Nielsen, M.; Lehre, K. P.; Danbolt, N. C. Brain Glutamate Transporter Proteins Form Homomultimers J. Biol. Chem. 1996, 271, 27715-27722
128. Lehre, K. P.; Danbolt, N. C. The Number of Glutamate Transporter Subtype Molecules at Glutamatergic Synapses: Chemical and Stereological Quantification in Young Adult Rat Brain J. Neurosci. 1998, 18, 8751-8757
129. Rothstein, J. D.; Dykes-Hoberg, M.; Pardo, C. A.; Bristol, L. A.; Jin, L.; Kuncl, R. W.; Kanai, Y.; Hediger, M. A.; Wang, Y.; Schielke, J. P.; Welty, D. F. Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate Neuron 1996, 16, 675-686
130. Rothstein, J. D.; Martin, L. J.; Kuncl, R. W. Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis N. Engl. J. Med. 1992, 326, 1464-1468
131. Maragakis, N. J.; Dykes-Hoberg, M.; Rothstein, J. D. Altered Expression of the Glutamate Transporter EAAT2b in Neurological Disease Ann. Neurol. 2004, 55, 469-477
132. Lin, C.-L. G.; Bristol, L. A.; Jin, L.; Dykes-Hoberg, M.; Crawford, T.; Clawson, L.; Rothstein, J. D. Aberrant RNA Processing in a Neurodegenerative Disease: The Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis Neuron 1998, 20, 589-602
133. Rothstein, J. D.; Kammen, M. V.; Levey, A. I.; Martin, L. J.; Kuncl, R. W. Selective Loss of Glial Glutamate Transporter GLT-1 in Amyotrophic Lateral Sclerosis Ann. Neurol. 1995, 38, 73-84
134. Bristol, L. A.; Rothstein, J. D. Glutamate Transporter Gene Expression in Amyotrophic Lateral Sclerosis Motor Cortex Ann. Neurol. 1996, 39, 676-679
135. Bendotti, C.; Tortarolo, M.; Suchak, S. K.; Calvaresi, N.; Carvelli, L.; Bastone, A.; Rizzi, M.; Rattray, M.; Mennini, T. Transgenic SOD1 G93A Mice Develop Reduced GLT-1 in Spinal Cord without Alterations in Cerebrospinal Fluid Glutamate Levels J. Neurochem. 2001, 79, 737-746
136. Rothstein, J. D.; Jin, L.; Dykes-Hoberg, M.; Kuncl, R. W. Chronic Inhibition of Glutamate Uptake Produces a Model of Slow Neurotoxicity Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6591-6595
137. Guo, H.; Lai, L.; Butchbach, M. E. R.; Stockinger, M. P.; Shan, X.; Bishop, G. A.; Lin, C.-l. G. Increased Expression of the Glial Glutamate Transporter EAAT2 Modulates Excitotoxicity and Delays the Onset but Not the Outcome of ALS in Mice Hum. Mol. Genet. 2003, 12, 2519-2532
138. Tovar-y-Romo, L. B.; Santa-Cruz, L. D.; Zepeda, A.; Tapia, R. Chronic Elevation of Extracellular Glutamate Due to Transport Blockade Is Innocuous for Spinal Motoneurons in Vivo Neurochem. Int. 2009, 54, 186-191
139. Volterra, A.; Trotti, D.; Tromba, C.; Floridi, S.; Racagni, G. Glutamate Uptake Inhibition by Oxygen Free Radicals in Rat Cortical Astrocytes J. Neurosci. 1994, 14, 2924-2932
140. Trotti, D.; Rolfs, A.; Danbolt, N. C.; Brown, R. H.; Hediger, M. A. SOD1 Mutants Linked to Amyotrophic Lateral Sclerosis Selectively Inactivate a Glial Glutamate Transporter Nat. Neurosci. 1999, 2, 427-433
141. MacDermott, A. B.; Mayer, M. L.; Westbrook, G. L.; Smith, S. J.; Barker, J. L. NMDA-receptor Activation Increases Cytoplasmic Calcium Concentration in Cultured Spinal Cord Neurones Nature 1986, 321, 519-522
142. 2+ Permeable AMPA Channels in Diseases of the Nervous System Front. Mol. Neurosci. 2011, 4, 1-7
143. 2+ Permeability of KA-AMPA-Gated Glutamate Receptor Channels Depends on Subunit Composition Science 1991, 252, 851-853
144. Carriedo, S. G.; Yin, H. Z.; Weiss, J. H. Motor Neurons Are Selectively Vulnerable to AMPA/Kainate Receptor-Mediated Injury in Vitro J. Neurosci. 1996, 16, 4069-4079
145. Greger, I. H.; Ziff, E. B.; Penn, A. C. Molecular Determinants of AMPA Receptor Subunit Assembly Trends Neurosci. 2007, 30, 407-416
146. Mayer, M. L. Glutamate Receptor Ion Channels Curr. Opin. Neurobiol. 2005, 15, 282-288
147. Kawahara, Y.; Ito, K.; Sun, H.; Aizawa, H.; Kanazawa, I.; Kwak, S. Glutamate Receptors: RNA Editing and Death of Motor Neurons Nature 2004, 427, 801
148. Burnashev, N.; Monyer, H.; Seeburg, P. H.; Sakmann, B. Divalent Ion Permeability of AMPA Receptor Channels Is Dominated by the Edited Form of a Single Subunit Neuron 1992, 8, 189-198
149. Kawahara, Y.; Kwak, S.; Sun, H.; Ito, K.; Hashida, H.; Aizawa, H.; Jeong, S.-Y.; Kanazawa, I. Human Spinal Motoneurons Express Low Relative Abundance of GluR2 mRNA: An Implication for Excitotoxicity in ALS J. Neurochem. 2003, 85, 680-689
150. 2+-Permeable AMPA Receptors in Neurological Disorders Trends Neurosci. 1997, 20, 464-470
151. Van Damme, P.; Braeken, D.; Callewaert, G.; Robberecht, W.; Van Den Bosch, L. GluR2 Deficiency Accelerates Motor Neuron Degeneration in a Mouse Model of Amyotrophic Lateral Sclerosis J. Neuropathol. Exp. Neurol. 2005, 64, 605-612
152. Tateno, M.; Sadakata, H.; Tanaka, M.; Itohara, S.; Shin, R.-M.; Miura, M.; Masuda, M.; Aosaki, T.; Urushitani, M.; Misawa, H.; Takahashi, R. Calcium-Permeable AMPA Receptors Promote Misfolding of Mutant SOD1 Protein and Development of Amyotrophic Lateral Sclerosis in a Transgenic Mouse Model Hum. Mol. Genet. 2004, 13, 2183-2196
153. Spalloni, A.; Albo, F.; Ferrari, F.; Mercuri, N.; Bernardi, G.; Zona, C.; Longone, P. Cu/Zn-Superoxide Dismutase (GLY93->ALA) Mutation Alters AMPA Receptor Subunit Expression and Function and Potentiates Kainate-Mediated Toxicity in Motor Neurons in Culture Neurobiol. Dis. 2004, 15, 340-350
154. G93A Transgenic Mice and Their Inhibition by a Noncompetitive Antagonist Ameliorates the Progression of Amytrophic Lateral Sclerosis-like Disease J. Neurosci. Res. 2006, 83, 134-146
155. Van Damme, P.; Leyssen, M.; Callewaert, G.; Robberecht, W.; Van Den Bosch, L. The AMPA Receptor Antagonist NBQX Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis Neurosci. Lett. 2003, 343, 81-84
156. Canton, T.; Böhme, G. A.; Boireau, A.; Bordier, F.; Mignani, S.; Jimonet, P.; Jahn, G.; Alavijeh, M.; Stygall, J.; Roberts, S.; Brealey, C.; Vuilhorgne, M.; Debono, M.-W.; Le Guern, S.; Laville, M.; Briet, D.; Roux, M.; Stutzmann, J.-M.; Pratt, J. RPR 119990, a Novel α-Amino-3-hydroxy-5- methyl-4-isoxazolepropionic Acid Antagonist: Synthesis, Pharmacological Properties, and Activity in an Animal Model of Amyotrophic Lateral Sclerosis J. Pharmacol. Exp. Ther. 2001, 299, 314-322
157. Rembach, A.; Turner, B. J.; Bruce, S.; Cheah, I. K.; Scott, R. L.; Lopes, E. C.; Zagami, C. J.; Beart, P. M.; Cheung, N. S.; Langford, S. J.; Cheema, S. S. Antisense Peptide Nucleic Acid Targeting GluR3 Delays Disease Onset and Progression in the SOD1 G93A Mouse Model of Familial ALS J. Neurosci. Res. 2004, 77, 573-582
158. Langford, S. J.; Cheema, S. S. Unpublished results.
159. Francis, K.; Bach, J. R.; DeLisa, J. A. Evaluation and Rehabilitation of Patients with Adult Motor Neuron Disease Arch. Phys. Med. Rehabil. 1999, 80, 951-963
160. Cheah, B. C.; Vucic, S.; Krishnan, A. V.; Kiernan, M. C. Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis Curr. Med. Chem. 2010, 17, 1942-1959
161. Bellingham, M. C. A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What Have We Learned in the Last Decade? CNS Neurosci. Ther. 2011, 17, 4-31
162. Traynor, B. J.; Alexander, M.; Corr, B.; Frost, E.; Hardiman, O. Effect of a Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic on ALS Survival: A Population Based Study, 1996-2000 J. Neurol. Neurosurg. Psychiatry 2003, 74, 1258-1261
163. Lacomblez, L.; Bensimon, G.; Leigh, P.; Debove, C.; Bejuit, R.; Truffinet, P.; Meininger, V. Long-Term Safety of Riluzole in Amyotrophic Lateral Sclerosis Amyotrophic Lateral Scler. 2002, 3, 23-29
164. Traynor, B. J.; Alexander, M.; Corr, B.; Frost, E.; Hardiman, O. An Outcome Study of Riluzole in Amyotrophic Lateral Sclerosis J. Neurol. 2003, 250, 473-479
165. Packer, J. E.; Slater, T. F.; Willson, R. L. Direct Observation of a Free Radical Interaction between Vitamin E and Vitamin C Nature 1979, 278, 737-738
166. Doba, T.; Burton, G. W.; Ingold, K. U. Antioxidant and Co-Antioxidant Activity of Vitamin C. The Effect of Vitamin C, Either Alone or in the Presence of Vitamin E or a Water-Soluble Vitamin E Analogue, upon the Peroxidation of Aqueous Multilamellar Phospholipid Liposomes Biochim. Biophys. Acta 1985, 835, 298-303
167. Frei, B.; England, L.; Ames, B. N. Ascorbate Is an Outstanding Antioxidant in Human Blood Plasma Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6377-6381
168. Gurney, M. E.; Cutting, F. B.; Zhai, P.; Doble, A.; Taylor, C. P.; Andrus, P. K.; Hall, E. D. Benefit of Vitamin E, Riluzole, and Gababapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis Ann. Neurol. 1996, 39, 147-157
169. Orrell, R. W.; Lane, R. J. M.; Ross, M. Antioxidant Treatment for Amyotrophic Lateral Sclerosis or Motor Neuron Disease Cochrane Database Syst. Rev. 2007, 1-30
170. Galbussera, A.; Tremolizzo, L.; Brighina, L.; Testa, D.; Lovati, R.; Ferrarese, C.; Cavaletti, G.; Filippin, G. Vitamin E Intake and Quality of Life in Amyotrophic Lateral Sclerosis Patients: A Follow-Up Case Series Study Neurol. Sci. 2006, 27, 190-193
171. Ascherio, A.; Weisskopf, M. G.; O'Reilly, E. J.; Jacobs, E. J.; McCullough, M. L.; Calle, E. E.; Cudkowicz, M.; Thun, M. J. Vitamin E Intake and Risk of Amyotrophic Lateral Sclerosis Ann. Neurol. 2005, 57, 104-110
172. Ferrante, R.; Klein, A.; Dedeoglu, A.; Flint Beal, M. Therapeutic Efficacy of EGb761 (Gingko biloba Extract) in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis J. Mol. Neurosci. 2001, 17, 89-96
173. Crow, J. P.; Calingasan, N. Y.; Chen, J.; Hill, J. L.; Beal, M. F. Manganese Porphyrin Given at Symptom Onset Markedly Extends Survival of ALS Mice Ann. Neurol. 2005, 58, 258-265
174. Wu, A. S.; Kiaei, M.; Aguirre, N.; Crow, J. P.; Calingasan, N. Y.; Browne, S. E.; Beal, M. F. Iron Porphyrin Treatment Extends Survival in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis J. Neurochem. 2003, 85, 142-150
175. Barber, S. C.; Mead, R. J.; Shaw, P. J. Oxidative Stress in ALS: A Mechanism of Neurodegeneration and a Therapeutic Target Biochim. Biophys. Acta 2006, 1762, 1051-1067
176. Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E. Neuroprotective Agents for Clinical Trials in ALS: A Systematic Assessment Neurology 2006, 67, 20-27
177. Kriz, J.; Nguyen, M. D.; Julien, J.-P. Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis Neurobiol. Dis. 2002, 10, 268-278
178. Zhu, S.; Stavrovskaya, I. G.; Drozda, M.; Kim, B. Y. S.; Ona, V.; Li, M.; Sarang, S.; Liu, A. S.; Hartley, D. M.; Wu, D. C.; Gullans, S.; Ferrante, R. J.; Przedborski, S.; Kristal, B. S.; Friedlander, R. M. Minocycline Inhibits Cytochrome c Release and Delays Progression of Amyotrophic Lateral Sclerosis in Mice Nature 2002, 417, 74-78
179. Gordon, P. H.; Moore, D. H.; Miller, R. G.; Florence, J. M.; Verheijde, J. L.; Doorish, C.; Hilton, J. F.; Spitalny, G. M.; MacArthur, R. B.; Mitsumoto, H.; Neville, H. E.; Boylan, K.; Mozaffar, T.; Belsh, J. M.; Ravits, J.; Bedlack, R. S.; Graves, M. C.; McCluskey, L. F.; Barohn, R. J.; Tandan, R. Efficacy of Minocycline in Patients with Amyotrophic Lateral Sclerosis: A Phase III Randomised Trial Lancet Neurol. 2007, 6, 1045-1053
180. Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y. H.; Bergles, D. E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D. S.; Toan, S. V.; Bruijn, L. I.; Su, Z.-z.; Gupta, P.; Fisher, P. B. β-Lactam Antibiotics Offer Neuroprotection by Increasing Glutamate Transporter Expression Nature 2005, 433, 73-77
181. Beghi, E.; Bendotti, C.; Mennini, T.; Miller, T.; Cleveland, D. Merits of a New Drug Trial for ALS? Science 2005, 308, 632b-633b
182. Pascuzzi, R. M.; Shefner, J.; Chappell, A. S.; Bjerke, J. S.; Tamura, R.; Chaudhry, V.; Clawson, L.; Haas, L.; Rothstein, J. D. A Phase II Trial of Talampanel in Subjects with Amyotrophic Lateral Sclerosis Amyotrophic Lateral Scler. 2010, 11, 266-271
183. Robinson, R. New ALS Drug Shows Dose-Dependent Efficacy in Phase 2 Trial Neurol. Today 2010, 10, 33-34
184. McGeer, E. G.; McGeer, P. L. Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis BioDrugs 2005, 19, 31-37
185. Zhang, W.; Narayanan, M.; Friedlander, R. M. Additive Neuroprotective Effects of Minocycline with Creatine in a Mouse Model of ALS Ann. Neurol. 2003, 53, 267-270
186. Kriz, J.; Gowing, G.; Julien, J.-P. Efficient Three-Drug Cocktail for Disease Induced by Mutant Superoxide Dismutase Ann. Neurol. 2003, 53, 429-436
187. Shin, J. H.; Cho, S. I.; Lim, H. R.; Lee, J. K.; Lee, Y. A.; Noh, J. S.; Joo, I. S.; Kim, K.-W.; Gwag, B. J. Concurrent Administration of Neu2000 and Lithium Produces Marked Improvement of Motor Neuron Survival, Motor Function, and Mortality in a Mouse Model of Amyotrophic Lateral Sclerosis Mol. Pharmacol. 2007, 71, 965-975
188. Dykxhoorn, D. M.; Novina, C. D.; Sharp, P. A. Killing the Messenger: Short RNAs that Silence Gene Expression Nat. Rev. Mol. Cell Biol. 2003, 4, 457-467
189. Ding, H.; Schwarz, D. S.; Keene, A.; Affar, E. B.; Fenton, L.; Xia, X.; Shi, Y.; Zamore, P. D.; Xu, Z. Selective Silencing by RNAi of a Dominant Allele That Causes Amyotrophic Lateral Sclerosis Aging Cell 2003, 2, 209-217
190. Raoul, C.; Abbas-Terki, T.; Bensadoun, J.-C.; Guillot, S.; Haase, G.; Szulc, J.; Henderson, C. E.; Aebischer, P. Lentiviral-Mediated Silencing of SOD1 through RNA Interference Retards Disease Onset and Progression in a Mouse Model of ALS Nat. Med. 2005, 11, 423-428
191. Ralph, G. S.; Radcliffe, P. A.; Day, D. M.; Carthy, J. M.; Leroux, M. A.; Lee, D. C. P.; Wong, L.-F.; Bilsland, L. G.; Greensmith, L.; Kingsman, S. M.; Mitrophanous, K. A.; Mazarakis, N. D.; Azzouz, M. Silencing Mutant SOD1 Using RNAi Protects against Neurodegeneration and Extends Survival in an ALS Model Nat. Med. 2005, 11, 429-433
192. Smith, R. A.; Miller, T. M.; Yamanaka, K.; Monia, B. P.; Condon, T. P.; Hung, G.; Lobsiger, C. S.; Ward, C. M.; McAlonis-Downes, M.; Wei, H.; Wancewicz, E. V.; Bennett, C. F.; Cleveland, D. W. Antisense Oligonucleotide Therapy for Neurodegenerative Disease J. Clin. Invest. 2006, 116, 2290-2296
193. Turner, B. J.; Cheah, I. K.; Macfarlane, K. J.; Lopes, E. C.; Petratos, S.; Langford, S. J.; Cheema, S. S. Antisense Peptide Nucleic Acid-Mediated Knockdown of the p75 Neurotrophin Receptor Delays Motor Neuron Disease in Mutant SOD1 Transgenic Mice J. Neurochem. 2003, 87, 752-763
194. Nagano, I.; Shiote, M.; Murakami, T.; Kamada, H.; Hamakawa, Y.; Matsubara, E.; Yokoyama, M.; Moritaz, K.; Shoji, M.; Abe, K. Beneficial Effects of Intrathecal IGF-1 Administration in Patients with Amyotrophic Lateral Sclerosis Neurol. Res. 2005, 27, 768-772
195. Sakowski, S. A.; Schuyler, A. D.; Feldman, E. L. Insulin-like Growth Factor-I for the Treatment of Amyotrophic Lateral Sclerosis Amyotrophic Lateral Scler. 2009, 10, 63-73
196. Sorenson, E. J.; Windbank, A. J.; Mandrekar, J. N.; Bamlet, W. R.; Appel, S. H.; Armon, C.; Barkhaus, P. E.; Bosch, P.; Boylan, K.; David, W. S.; Feldman, E.; Glass, J.; Gutmann, L.; Katz, J.; King, W.; Luciano, C. A.; McCluskey, L. F.; Nash, S.; Newman, D. S.; Pascuzzi, R. M.; Pioro, E.; Sams, L. J.; Scelsa, S.; Simpson, E. P.; Subramony, S. H.; Tiryaki, E.; Thornton, C. A. Subcutaneous IGF-1 Is Not Beneficial in 2-Year ALS Trial Neurology 2008, 71, 1770-1775